The substantial outperformance of Eli Lilly and Co over the past 5 years, as indicated by its 43.59% annualized return, suggests a strong and positive impact on its stock price in the short term. This performance, coupled with a significant market capitalization of $741.67 billion, highlights the company's robust financial health and growth prospects. Investors may view this historical performance as indicative of future potential, likely contributing to positive sentiment and possibly driving the stock price up in the short term.